Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?

× No keyword cloud information.

14 in total

1. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.

Authors:
Journal: Am J Kidney Dis Date: 2004-05 Impact factor: 8.860

2. Role of aldosterone in the remnant kidney model in the rat.

Authors: E L Greene; S Kren; T H Hostetter
Journal: J Clin Invest Date: 1996-08-15 Impact factor: 14.808

Review 3. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II.

Authors: Rhian M Touyz
Journal: Exp Physiol Date: 2005-05-12 Impact factor: 2.969

4. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.

Authors: Fiona Turnbull; Bruce Neal; Charles Algert; John Chalmers; Neil Chapman; Jeff Cutler; Mark Woodward; Stephen MacMahon
Journal: Arch Intern Med Date: 2005-06-27

5. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients.

Authors: Julia M Steinke; Alan R Sinaiko; Michael S Kramer; Samy Suissa; Blanche M Chavers; Michael Mauer
Journal: Diabetes Date: 2005-07 Impact factor: 9.461

6. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.

Authors: R O Estacio; B W Jeffers; N Gifford; R W Schrier
Journal: Diabetes Care Date: 2000-04 Impact factor: 19.112

7. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Authors: Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen
Journal: N Engl J Med Date: 2004-10-31 Impact factor: 91.245

8. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190

ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?

1. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.

2. Role of aldosterone in the remnant kidney model in the rat.

Review 3. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II.

4. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.

5. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients.

6. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.

7. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

8. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

9. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Review 10. Microalbuminuria: what is it? Why is it important? What should be done about it? An update.

1. Control of blood pressure: does it matter which agent you use?

Review 2. Identification and management of albuminuria in the primary care setting.